Clinical Trials Logo

Filter by:
NCT ID: NCT02974322 Withdrawn - Crohn Disease Clinical Trials

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease. The study will test GED-0301 compare to placebo for 12 weeks. The study treatment is blinded which means that patients and the study doctor will not know which treatment has been assigned. Patients in this study will be allowed treatment with stable doses of oral aminosalicylates, oral corticosteroids, immunosupressants and antibiotics for the treatment of Crohn's disease. Adolescent patients will also be allowed treatment with stable doses of exclusive enteral nutrition and growth hormone. All patients who complete the study will have the option to enter a long term active treatment study.

NCT ID: NCT02970903 Withdrawn - Critical Care Clinical Trials

VitalPAD: an Intelligent Monitoring and Communication Device to Optimize Safety in the PICU

Start date: October 2016
Phase: N/A
Study type: Interventional

The VitalPAD is a unified, portable and intelligent device that integrates information from multiple patient monitors, mechanical ventilators, infusion pumps and clinical information systems on a mobile platform. It will allow nurses, respiratory therapists and physicians to continuously monitor and coordinate care of critically ill patients. This study will use a participatory design process to guide the design of an integrated mobile device, followed by an evaluation of the proposed device in a simulated ICU setting.

NCT ID: NCT02953145 Withdrawn - Cleft Palate Clinical Trials

The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery

Start date: September 1, 2019
Phase: Phase 4
Study type: Interventional

Cleft Palate is a condition which affects up to 1 in 500 live births. Current treatment is surgery to correct the underlying anomaly. Children born with cleft palate typically undergo surgery at age 12 months. Standard ways to stop surgical bleeding include direct pressure and the use of electrocautery (burning of the tissue). Other products are available to help lessen blood loss. One of these includes a fibrin sealant. Fibrin is the key component of a blood clot. When a fibrin sealant is applied there are a variety of potential benefits other than bleeding control. One of these is decreased pain post operatively It is the investigators belief that the use of a fibrin sealant, Tisseel, in cleft palate surgery will decrease pain and enhance the recovery of children who undergo cleft palate repair. The proposed study will randomly select children undergoing cleft palate repair to have tisseel used on the incision. Through statistical tests 40 children will be recruited (20 to have tisseel used and 20 with no tisseel). The use of tisseel will be known to the surgeon but not to the recovery room or ward nursing staff. Post operatively, the FLACC pain scale will be used to score the pain of the children throughout their admission to the Stollery children's hospital. The amount of pain controlling medication required as well as time to discharge will also be recorded. Statistical analysis of the data will be performed using accepted methods. Overall, the investigators hope to show that fibrin sealant, tisseel, will less the amount of post operative pain experienced by children undergoing cleft palate repair.

NCT ID: NCT02952196 Withdrawn - Clinical trials for Amphetamine Addiction

Cannabioids as a New Intervention for Amphetamine Dependence

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02947243 Withdrawn - Pain Clinical Trials

Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: Trial

DREAM-T
Start date: May 2018
Phase: N/A
Study type: Interventional

Children with burn injuries experience severe pain intensity during medical procedures despite the increasing doses of analgesics. Current guidelines on pediatric procedural pain management recommend the combination of non-pharmacological and pharmacological interventions to enhance pain management and decrease the numerous side effects of analgesics. Virtual reality (VR) has gained growing consideration as a non-pharmacological method as it engages multiple senses and allows interactions with a virtual world. Oculus Rift ® is a new technology in VR that provides more immersiveness, at a relatively low cost, and could probably improve the management of pain and anxiety in burn care. It also has the potential, with appropriate custom software designed for burn pediatric patients, to reduce the cybersickness symptoms (nausea, dizziness) associated with VR. To the knowledge of the investigators, none of the pediatric hospitals across Canada have tested VR as a method of pain and anxiety management in children with burn injuries. Overall hypotheses: VR distraction via Oculus Rift ® could be an effective method to relieve pain, and anxiety, as well as a less traumatizing hospital experience, while promoting a more humanistic care environment by combining new technologies (VR via Oculus Rift ®) to standard analgesic interventions administered to these children. The expected results will have a direct effect on physical (pain) and psychological (anxiety, pain memories) health of the child. In addition, clinical implications may include other indicators of quality of care and economic benefits such as a wider range of motion of burned limbs and reduction in dosage of opioids and anxiolytic drugs administered.

NCT ID: NCT02904772 Withdrawn - LPL Deficiency Clinical Trials

Alipogene Tiparvovec for the Treatment of LPLD Patients

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range of parameters), and "the metabolic response" (postprandial CM metabolism) in LPLD patients with and without an immunosuppressant regimen.

NCT ID: NCT02904746 Withdrawn - Clinical trials for Mental Health Crisis

Intervention to Increase Treatment Engagement Among Individuals Referred for Post-Crisis Mental Health Services

Start date: October 2016
Phase: N/A
Study type: Interventional

This study will evaluate the preliminary effectiveness of Make It!, a single 15-minute intervention aimed at increasing attendance to a follow-up appointment for psychological services (i.e., an information class) among clients accessing walk-in services at a mental health crisis response centre. As a secondary aim, we will examine the demographic correlates, presenting problems, and symptom correlates of clients who do and do not attend follow-up services.

NCT ID: NCT02900183 Withdrawn - Clinical trials for Alpha-1 Antitrypsin Deficiency

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post last dose.

NCT ID: NCT02899325 Withdrawn - Clinical trials for Hepatocellular Carcinoma

FDGal PET/CT to Detect Hepatocellular Carcinoma

Start date: October 2019
Phase:
Study type: Observational

Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection. This study proposes to use 18F-FGal and 18F-FDG PET/CT scans to compare the clinical efficacy of diagnosing hepatocellular carcinoma (a type of liver cancer) using these PET/CT scans.

NCT ID: NCT02892032 Withdrawn - Chronic Pain Clinical Trials

Attention Training Trial

Start date: August 2016
Phase: N/A
Study type: Interventional

This study aims to examine the effects of smartphone-based Attention-Bias Modification Training (ABMT) in chronic pain participants.